bridge4

Clinical Pharmacology of Miami

Miami Lakes, FL

CPMI Overview

Follow Us On Social Media:
Facebook
Twitter

Principal Investigators

  • Kenneth C. Lasseter, MD
    Board Certified Cardiology & Internal Medicine
  • Samuel Oberstein, MD
    Board Certified, Obstetrics and Gynecology
  • Antoinette M. Sulpizi, MD
    Board Certified, Internal Medicine and Cardiology

Site Contact
Stacy C. Dilzer, R.N., B.S.N.

Specialties

  • Complex Early Phase Inpatient Trials
  • Hepatic & Renal Impairment
  • NASH
  • Diabetic Type 2
  • Sexual Dysfunction
  • First-In-Man Studies
  • Post-Menopausal
  • Smoking Cessation
  • Geriatric
  • Healthy Volunteer
  • TQT/QTc
  • Cardiac Safety Studies / Early Cardiac Safety Assessment
  • Food Effect
  • First to File
  • Hypertension
  • Obesity
  • Drug-Drug Interaction
  • 505(b)(2)

Facility

  • 24,000 Square Foot Inpatient & Outpatient Unit
  • 120 Research Beds
  • Secure, Alarm-Monitored Pharmacy Department and Double-Locked Drug Storage Room
  • Environmental Monitoring System
  • Large, Secure PK Processing Lab
  • -20 to -70 Degree Sample Storage
  • QTc Clinical Trial ECG Monitored Research Areas
  • 24 Hour CCTV Recording
  • 40-Watt Natural Gas Generator

Institutional Review Board
Central

Contact
info@cnssites.com
+1-908-756-4411

Social Media

News Feed

May, 2017: CPMI joined Evolution Research Group less than a year ago, and has been a tremendous addition to the Evolution Research Group organization. They work closely with their clinical research organization and sponsor clients to deliver high quality data, on time and within budget. With Evolution Research Group’s infrastructure relieving CPMI of the burden of financial and administrative responsibilities, the clinical operations team has been able to flourish and offer expanded services to the industry. CPMI has a 30-year history of providing its clients with unique capabilities, executing on complex trials in normal healthy volunteers and highly specialized populations. Well known for its ability to enroll in studies targeting renal insufficiency, hepatic impairment, T2DM, dermatology, elderly healthy subjects, post-menopausal women, sexual dysfunction (male and female), smoking cessation and obesity, CPMI continues to expand into new indications. The 120-bed Phase I unit is a preferred site for many large pharmaceutical sponsors, biotechnology and specialty pharmaceutical companies. Additionally, several clinical research organization clients trust CPMI’s established team to deliver when their own Phase I units are at capacity or a multi-center approach is needed. With veterans Dr. Kenneth Lasseter, Stacy Dilzer and Cooper Shamblen leading the team, CPMI has successfully completed hundreds of FIM, PK/PD, SAD/MAD, DDI, TQT, food effect, and BA/BE studies. Evolution Research Group’s service offering is greatly enhanced by CPMI’s clinical pharmacology expertise, enabling Evolution Research Group to meet its clients’ needs throughout the lifecycle of a compound’s development.